Three-fourths of patients have 70-75% improvement at 16 weeks with zasocitinib, envudeucit ...

Foxglove, a flowering plant long feared for its toxicity, became an unlikely source of a widely studied heart drug. Digoxin, ...

Thought LeadersAoife Hayes, Kevin O'Regan & Julie ScanlonClinical Trials Assitant, Operations Manager & Quality Assurance ManagerAtlantia Clinical Trials Food clinical trials may not be as familiar to ...

Felicione is an independent clinical research scientist and principal investigator. Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising ...

Targeted indoor residual spraying focuses insecticide applications on common resting surfaces of Aedes aegypti mosquitoes (an arboviral disease vector) in houses, such as exposed lower sections of ...

Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes First-Line Nivolumab Plus Relatlimab Versus ...

Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic ...